Illumina Partners with SomaLogic to help Researchers
Illumina Partners with SomaLogic – The Illumina, Inc. (NASDAQ: ILMN) has expressed interest in developing the SomaScan® Proteomics Assay for the company’s current and future next-generation sequencing (NGS) platforms. Proteomics is growing rapidly in the high throughput segments due to this partnership. NGS technology from Illumina allows researchers to make more precise and timely connections between genetic sequences (genotypes) and cellular functions (phenotypes), which provides researchers with more opportunities to contribute to the clinical world.
In addition to deepening researchers’ understanding of biology and disease, proteomics is a natural extension of genomics, but previously conducting proteomics experiments at scale was difficult, since large numbers of proteins (ultra-high complex) must be analyzed. Scientists will be able to investigate thousands of samples for over 10,000 protein targets by combining high-complexity Somascan® technology with Illumina’s existing and future high throughput NGS systems. With the help of simple, automated analysis and cost-saving strategies, this capability will grow over time.
Through the agreement, Illumina intends to combine SomaLogic’s protein target technology with Illumina’s sequencing technology, informatics toolset, and DRAGENTM software to create an end-to-end NGS workflow solution.
NGS provides biological insights at scale that can help us better understand how proteins contribute to cellular health and function,” said Alex Aravanis, Chief Technology Officer at Illumina. With our partnership with SomaLogic, we’ll be able to conduct more sophisticated, high-throughput multi-omic studies for existing and future NGS customers.”
Roy Smythe, M.D., SomaLogic Chief Executive Officer, said, “This partnership brings together unique capabilities that will impact human health profoundly in the process of understanding, avoiding, and treating disease.”
Illumina Partners with SomaLogic
Several recent market reports estimate the proteomics market to be worth about $50 billion, with high-throughput technologies among the fastest-growing segments within the industry. Through the development of its scalable NGS platforms and its extensive installed base across academic research institutions, medical centers, and biopharmaceutical companies, SomaLogic will expand its market-leading protein panel, supporting its expansion into proteomics.
At the 40th Annual J.P. Morgan Healthcare Conference on Jan. 10, 2022, Illumina will present on this partnership and other business updates.
By unlocking the power of the genome, Illumina is improving the health of people around the world. In the research, clinical, and applied markets, we serve customers with DNA sequencing and array-based technologies; our focus on innovation has established us as a global leader. A variety of applications are available for our products, including life sciences, oncology, reproductive health, agriculture, and many others. You can find out more at www.illumina.com or through our social media accounts on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Read more Skill Development News on CSR Today.